TP53 and small cell lung carcinoma: Osimertinib given as a second-line treatment eliminated the <i>EGFR</i>-T790M population and simultaneously consolidated the proliferation of the <i>TP53</i> + <i>RB1</i> clone that eventually led to the histologic transformation to small-cell lung cancer (SCLC).